Evidence map›Paper›PMID 37202895›Full record

ArticleCurrent computer-aided drug design2024

Assessment of Anticholinergic and Antidiabetic Properties of Some Natural and Synthetic Molecules: An

Veysel Çomaklı, İmdat Aygül, Rüya Sağlamtaş, Müslüm Kuzu, Ramazan Demirdağ, Hülya Akincioğlu, Şevki Adem, İlhami Gülçin

Abstract read
PubMed Publisher
In one paragraph

Article in Current computer-aided drug design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Veysel ÇomaklıDepartment of Nutrition and Dietetics, İbrahim Çeçen University of Ağrı, Ağrı, Türkiye.ORCID 0000-0003-2109-6702
İmdat AygülDepartment of Nutrition and Dietetics, Gümüşhane University, Gümüşhane, Türkiye.ORCID 0000-0002-7811-1726
Rüya SağlamtaşDepartment of Medical Services and Techniques, İbrahim Çeçen University of Ağrı, Ağrı, Türkiye.ORCID 0000-0003-0283-7448
Müslüm KuzuDepartment of Nutrition and Dietetics, Karabük University, Karabük, Türkiye.ORCID 0000-0002-1375-7673
Ramazan DemirdağDepartment of Nutrition and Dietetics, İbrahim Çeçen University of Ağrı, Ağrı, Türkiye.ORCID 0000-0003-3493-7056
Hülya AkincioğluDepartment of Chemistry, İbrahim Çeçen University of Ağrı, Ağrı, Türkiye.ORCID 0000-0001-5453-0953
Şevki AdemDepartment of Chemistry, Çankırı Karatekin University, Çankırı, Türkiye.ORCID 0000-0003-2146-5870
İlhami GülçinDepartment of Chemistry, Atatürk University, Erzurum, Türkiye.ORCID 0000-0001-5993-1668
Ağrı İbrahim Çeçen University · TRAtatürk University · TRÇankırı Karatekin University · TRGümüşhane University · TRKarabük University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aimed to determine the

backgroundAlzheimer's disease (AD) and Type II diabetes mellitus (T2DM) are considered the most important diseases of today's world. However, the side effects of therapeutic agents used in both diseases limit their use. Therefore, developing drugs with high therapeutic efficacy and better pharmacological profile is important.

objectivesThis study sets out to determine the related enzyme inhibitors used in treating AD and T2DM, considered amongst the most important diseases of today's world.

methodsIn the current study, the

resultsAll the molecules showed an inhibitory effect on the enzymes. The IC

conclusionAccording to the results obtained, the molecules used in the study may be considered potential inhibitor candidates for AChE, BChE and α-glycosidase.

Indexed as

AcetylcholinesteraseButyrylcholinesteraseCholinesterase InhibitorsComputer SimulationHypoglycemic Agentsalpha-GlucosidasesAlzheimer DiseaseCholinergic AntagonistsDiabetes Mellitus, Type 2Glycoside Hydrolase InhibitorsHumansMolecular Docking SimulationAcetylcholinesterasealpha-GlucosidasesButyrylcholinesteraseCholinergic AntagonistsCholinesterase InhibitorsGlycoside Hydrolase InhibitorsHypoglycemic AgentsacetylcholinesteraseAlzheimer's diseasebutyrylcholinesteraseinhibitionMolecular modellingtype II diabetes mellitusα-glycosidase.

Identifiers

PMID37202895
OpenAlexW4377092624

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.